ANNX | Annexon, Inc. | [NASD]
Index- P/E- EPS (ttm)-2.47 Insider Own0.10% Shs Outstand73.86M Perf Week-51.69%
Market Cap111.49M Forward P/E- EPS next Y-2.17 Insider Trans- Shs Float46.49M Perf Month-47.51%
Income-145.30M PEG- EPS next Q-0.54 Inst Own100.70% Short Float / Ratio4.39% / 3.11 Perf Quarter-47.22%
Sales- P/S- EPS this Y23.70% Inst Trans29.93% Short Interest2.04M Perf Half Y-50.86%
Book/sh2.91 P/B0.98 EPS next Y0.90% ROA-53.40% Target Price17.00 Perf Year-7.77%
Cash/sh5.83 P/C0.49 EPS next 5Y38.60% ROE-66.40% 52W Range2.07 - 7.65 Perf YTD-44.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.75% Beta-
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low37.68% ATR0.64
Employees80 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)31.05 Volatility20.76% 11.12%
OptionableYes Debt/Eq0.00 EPS Q/Q42.90% Profit Margin- Rel Volume9.83 Prev Close2.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume656.26K Price2.85
Recom1.70 SMA20-46.99% SMA50-41.18% SMA200-48.19% Volume6,448,057 Change35.71%
Date Action Analyst Rating Change Price Target Change
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
May-26-23 03:05AM
May-25-23 11:52AM
May-24-23 04:01PM
May-16-23 04:01PM
04:01PM Loading…
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
06:30AM Loading…
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
06:30AM Loading…
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
Jan-04-22 04:05PM
Dec-31-21 08:30AM
Dec-13-21 09:00AM
Nov-30-21 05:24AM
Nov-28-21 11:17AM
Nov-09-21 04:01PM
Oct-19-21 06:38AM
Oct-04-21 10:49AM
Sep-23-21 06:30AM
Sep-20-21 06:30AM
Sep-16-21 11:30AM
Aug-16-21 04:01PM
Jul-22-21 07:00AM
May-21-21 06:30AM
May-17-21 04:05PM
May-05-21 07:00AM
Apr-22-21 01:47AM
Mar-25-21 07:00AM
Mar-01-21 01:11PM
Feb-08-21 07:00AM
Jan-12-21 07:00AM
Jan-05-21 07:00AM
Dec-21-20 07:00AM
Dec-11-20 01:15PM
Nov-16-20 04:01PM
Nov-12-20 04:05PM
Oct-24-20 10:13AM
Sep-08-20 04:01PM
Jul-30-20 08:00AM
Jul-28-20 04:05PM
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barre syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Love DouglasPresident & CEOFeb 15Sale5.876,57138,564197,646Feb 17 05:12 PM
Lew JenniferEVP & Chief Financial OfficerFeb 14Sale6.301661,04629,542Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 14Sale6.3014490727,805Feb 15 07:00 PM
Lew JenniferEVP & Chief Financial OfficerFeb 13Sale6.311,74210,98929,708Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 13Sale6.301,5019,46127,949Feb 15 07:00 PM
Satter Muneer ADirectorFeb 10Buy6.802,647,05817,999,9947,056,024Feb 14 04:31 PM
Satter Muneer ADirectorJul 07Buy3.842,453,9889,423,3144,408,966Jul 11 08:42 PM